Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

SRCircumventing imatinib resistance.

Michael W N Deininger1, Brian J Druker

  • 1Oregon Health & Science University Cancer Institute, Center for Hematologic Malignancies, L592, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.

Cancer Cell
|August 25, 2004
PubMed
Summary

Imatinib resistance in chronic myeloid leukemia is often caused by BCR-ABL mutations. New ABL inhibitors show promise in overcoming these mutations, offering hope for patients with relapsed disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

American journal of hematology·2026
Same author

Results of a phase 1 trial testing ruxolitinib plus venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Blood neoplasia·2026
Same author

Clinical outcomes of older patients with NPM1-mutated or KMT2A-rearranged AML before menin inhibitors: a Beat AML report.

Blood advances·2026
Same author

DDX41-Mutated AML: A Case Report and Perspectives.

JCO precision oncology·2026
Same author

The aryl hydrocarbon receptor is associated with monocytic AML and innate immune resistance reversible with an AHR inhibitor.

Frontiers in immunology·2025
Same author

<i>IDH2</i> mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy.

Haematologica·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Imatinib is a key therapy for chronic myeloid leukemia (CML).
  • Relapse in CML patients treated with imatinib is frequently linked to BCR-ABL gene mutations.
  • These mutations confer resistance to imatinib therapy.

Purpose of the Study:

  • To investigate alternative ABL inhibitors targeting BCR-ABL mutations.
  • To understand the structural mechanisms of action and resistance related to these inhibitors.
  • To evaluate the efficacy of novel inhibitors against common BCR-ABL mutations.

Main Methods:

  • Identification and characterization of alternative ABL inhibitors.
  • Structural analysis to elucidate drug-target interactions.
  • Preclinical studies assessing inhibition of BCR-ABL mutants.

Main Results:

  • Several alternative ABL inhibitors effectively target common BCR-ABL mutations.
  • Structural studies provide insights into inhibitor mechanisms and resistance pathways.
  • One novel inhibitor has advanced to clinical trials.

Conclusions:

  • Alternative ABL inhibitors represent a promising strategy for managing imatinib-resistant CML.
  • Understanding resistance mechanisms is crucial for developing effective targeted therapies.
  • Integrated scientific and clinical studies are vital for therapeutic advancement.

Related Experiment Videos